Rituximab and mycophenolate mofetil in interstitial lung disease (EVER-ILD): 1-year follow-up results of a randomised controlled trial.
Mansy L, Caille A, Reynaud-Gaubert M, Bermudez J, Bonniaud P, Borie R, Brillet PY, Cadranel J, Court-Fortune I, Crestani B, Debray MP, Duprez M, Guillaumot A, Hirschi-Santelmo S, Israel-Biet D, Jouneau S, Juvin K, Kerjouan M, Mankikian J, Marquette CH, Naccache JM, Nunes H, Plantier L, Prevot G, Quetant S, Traclet J, Valentin V, Uzunhan Y, Wémeau-Stervinou L, Cottin V, Marchand-Adam S; EVER-ILD investigators and the OrphaLung network.
Mansy L, et al. Among authors: duprez m.
Eur Respir J. 2024 Sep 12;64(3):2401368. doi: 10.1183/13993003.01368-2024. Print 2024 Sep.
Eur Respir J. 2024.
PMID: 39231630
Clinical Trial.
No abstract available.